NIH R01 · 2024
Genetic Analysis of Myeloproliferative Disease
Abstract The stem cell leukemia/lymphoma syndrome (SCLL) is unique in that it is the only cancer syndrome that results consistently from the ligand independent activation of FGFR1 tyrosine kinase. Presenting as a myeloproliferative disorder it rapidly progresses to AML and in many cases patients develop biphenotypic T- cell or B-cell lymphomas. The consensus thinking is that FGFR1 promotes a stem cell expansion which can progress and develop depending on the subsequent acquisition of oncogenic events. This disease provides a unique opportunity to investigate basic genetic events associated with maintenance of a stem cell phenotype as well as the events that allow progression to AML. We have…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.